KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non Operating Income: 2016-2024

Historic Non Operating Income for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to -$304.3 million.

  • Amneal Pharmaceuticals' Non Operating Income fell 2.97% to -$75.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$289.2 million, marking a year-over-year increase of 6.97%. This contributed to the annual value of -$304.3 million for FY2024, which is 24.40% down from last year.
  • Amneal Pharmaceuticals' Non Operating Income amounted to -$304.3 million in FY2024, which was down 24.40% from -$244.6 million recorded in FY2023.
  • Amneal Pharmaceuticals' 5-year Non Operating Income high stood at -$121.3 million for FY2021, and its period low was -$304.3 million during FY2024.
  • For the 3-year period, Amneal Pharmaceuticals' Non Operating Income averaged around -$234.1 million, with its median value being -$244.6 million (2023).
  • In the last 5 years, Amneal Pharmaceuticals' Non Operating Income tumbled by 546.33% in 2020 and then increased by 4.40% in 2021.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Non Operating Income stood at -$126.9 million in 2020, then climbed by 4.40% to -$121.3 million in 2021, then declined by 26.25% to -$153.2 million in 2022, then slumped by 59.69% to -$244.6 million in 2023, then fell by 24.40% to -$304.3 million in 2024.